The drug aducanumab could be approved in the US and EU soon. It effectively combats the amyloid beta plaques in the brain that are indicative of Alzheimer’s disease. But does it also slow down memory...
Bioelectronic medicine is embryonic. But British drugmaker GlaxoSmithKline and US tech firm Alphabet see its potential. With one eye on research and another on your data, they will jointly invest millions. Look around the web...